Molecular target
Adenosine Receptor System
Inhibitory neuromodulatory system. Caffeine and other methylxanthines act as competitive antagonists at A1 and A2A receptors, producing wakefulness and increased alertness.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on Adenosine Receptor System
These medications have Adenosine Receptor System among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on Adenosine Receptor System
Each plant below contains a named compound documented to act on Adenosine Receptor System. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- CaffeineXanthine alkaloid
Competitive, non-selective adenosine receptor antagonism and phosphodiesterase inhibition; responsible for CNS stimulant and mild diuretic effects noted in traditional use records.
- TheobromineXanthine alkaloid
Weaker adenosine receptor antagonist than caffeine; shares xanthine-class mechanism with theophylline. Investigated for mild vasodilatory and diuretic effects.
- CaffeineMethylxanthine alkaloid
Guaraná seeds contain 4-6% caffeine by weight — among the highest natural caffeine concentrations known. Tannin-bound, slowly released — produces a smoother stimulation profile than coffee.
- Theobromine, theophyllineMethylxanthine alkaloid
Auxiliary methylxanthines contributing to overall stimulant profile.
- Caffeine (mateina)Methylxanthine alkaloid
Same caffeine pharmacology as coffee — adenosine A1/A2A antagonism. Content ~80 mg per 200 ml serving.
- TheobromineMethylxanthine alkaloid
Cocoa-shared methylxanthine; weaker CNS effect, modest cardiovascular activity.
- CaffeineMethylxanthine alkaloid
Competitive antagonist at adenosine A1 and A2A receptors — the primary mechanism of wakefulness, alertness, and cognitive arousal. Also weak phosphodiesterase inhibition at higher concentrations. CYP1A2 substrate — slow metabolizers experience more cardiovascular effects per dose.
- CaffeineMethylxanthine alkaloid
Adenosine A1/A2A antagonist — basis for wakefulness and cognitive arousal effects.
- Cordycepin (3'-deoxyadenosine)Nucleoside analog
Adenosine analog with modulating activity at adenosine receptors; mitochondrial biogenesis effects in preclinical models.